Join the Rybelsus group to help and get support from people like you.
Rybelsus News (Page 3)
GLP-1 Receptor Agonist Use Increases Likelihood of Antidepressant Prescription
WEDNESDAY, May 15, 2024 – Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a study published...
More Studies Support Wegovy's Long-Term Weight-Loss Benefits
TUESDAY, May 14, 2024 – Semaglutide – the active ingredient in the blockbuster weight-loss drugs Ozempic and Wegovy – can produce long-term weight and heart health benefits, a pair of new studies...
Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV
TUESDAY, April 30, 2024 – For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter published online...
GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer
WEDNESDAY, April 24, 2024 – Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online...
Endoscopic Sleeve Gastroplasty Is Cost Saving Versus Semaglutide
FRIDAY, April 12, 2024 – For individuals with class II obesity, endoscopic sleeve gastroplasty (ESG) is cost saving compared with semaglutide, according to a study published online April 12 in JAMA...
Aspiration Pneumonia Risk Increased for GLP-1 RA Users Undergoing Endoscopy
FRIDAY, April 12, 2024 – Patients using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) undergoing endoscopic procedures have an increased risk for aspiration pneumonia, according to a study...
Ozempic, Wegovy Won't Boost Thyroid Cancer Risk: Study
WEDNESDAY, April 10, 2024 – Wegovy, Ozempic and other drugs known as GLP-1 analogues have become wildly popular for controlling diabetes and helping folks lose weight. There were concerns that...
ACC: Semaglutide Beneficial in Obesity-Related Heart Failure, Type 2 Diabetes
TUESDAY, April 9, 2024 – Semaglutide leads to larger reductions in heart failure-related symptoms and physical limitations among patients with obesity-related heart failure with preserved ejection...
AANA Issues Considerations for GLP-1 Receptor Agonist Use Before Surgery
TUESDAY, March 19, 2024 – Considerations for anesthesia care in relation to use of glucagon-like peptide-1 (GLP-1) receptor agonists before surgery are addressed in a report published March 11 by...
GLP-1 RA Reduces Severity of Steatotic Liver Disease in People With HIV
MONDAY, March 18, 2024 – For people with HIV (PWH) with metabolic-associated steatotic liver disease (MASLD), semaglutide is associated with absolute and relative declines in intrahepatic...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
Risk for Suicidal Ideation Not Increased With Semaglutide
TUESDAY, Jan. 9, 2024 – For individuals with overweight or obesity and type 2 diabetes, semaglutide is not associated with an increased risk for suicidal ideation compared with non-glucagon-like...
Consumption of Ultra-Processed Foods Tied to Upper Digestive Tract Cancers
FRIDAY, Dec. 22, 2023 – Higher ultra-processed food (UPF) consumption is associated with a greater risk for head and neck cancer (HNC) and esophageal adenocarcinoma (OAC), according to a study...
Use of Noninsulin Antidiabetic Meds Increasing for T2D in Pregnancy
WEDNESDAY, Dec. 13, 2023 – Use of second-line noninsulin antidiabetic medications (ADMs) is increasing for type 2 diabetes (T2D) in pregnancy, but use is not associated with a significantly...
Risk for CRC Reduced With GLP-1RAs for Drug-Naive Patients With T2D
MONDAY, Dec. 11, 2023 – For drug-naive patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1RAs) are associated with a reduced risk for colorectal cancer (CRC)...
Ask a question
To post your own question to this support group, sign in or create an account.